Ruipuchenchuang key facts
as of Oct 2026- Developer of advanced biomedical solutions designed for regenerative stem cell medicine.
- Ruipuchenchuang is valued at approximately $300.4M as of Oct 2026 (last reported valuation).
- It has raised $84.3M; the latest was Later Stage VC ($70.3M) in Nov 2025.
- Notable investors include Lenovo Capital and Incubator Group, YuanBio Venture Capital, Hangzhou Dongfang Jiafu Asset Management, Lotus Lake Ventures, Jiangsu Huarui Investment — 12 tracked in total.
- Status: Privately Held (backing).
Ruipuchenchuang's last reported valuation, Nov 2024. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Ruipuchenchuang: the Monday email on marks, rounds and moves
Ruipuchenchuang funding rounds
No funding rounds for Ruipuchenchuang are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ruipuchenchuang
12+Membership and data by Private Market View
Ruipuchenchuang valuation
Ruipuchenchuang's last reported valuation was $300 million in Nov 2024. No priced round, secondary trade or fund mark has surfaced since.
Ruipuchenchuang investors
12 investors are on record for Ruipuchenchuang, including Lenovo Capital and Incubator Group, YuanBio Venture Capital, Hangzhou Dongfang Jiafu Asset Management and Lotus Lake Ventures.
About Ruipuchenchuang
Developer of advanced biomedical solutions designed for regenerative stem cell medicine. The company offers pioneering stem cell therapies using proprietary human pluripotent stem cell technology, cell differentiation processes, clinical-grade manufacturing, and preclinical safety evaluation, thereby enabling innovative treatment options in the field of regenerative medicine.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2014
- Employees
- 19
- Website
- reprogenix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.